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a  b  s  t  r  a  c  t
Infection  with  human  inﬂuenza  virus  leads  to serious  respiratory  disease.  Vaccination  is the  most  common
and effective  prophylactic  measure  to prevent  inﬂuenza.  Inﬂuenza  vaccine  manufacturing  and  release
is controlled  by  the  correct  determination  of  the  potency-deﬁning  haemagglutinin  (HA)  content.  This
determination  is historically  done  by single  radial  immunodiffusion  (SRID),  which  utilizes  a  statistical
slope-ratio  model  to estimate  the  actual  HA  content.  In this  paper  we describe  the  development  and
qualiﬁcation  of  a parallel  line  model  for  analysis  of  HA quantiﬁcation  by  SRID  in  cell  culture-derived
whole  virus  ﬁnal  monovalent  and  trivalent  inﬂuenza  vaccines.  We  evaluated  plate  layout,  sample  ran-
domization,  and  validity  of  data  and  statistical  model.  The  parallel  line  model  was  shown  to  be robust  andarallel line model
aemagglutinin quantiﬁcation
reproducible.  The  precision  studies  for  HA  content  demonstrated  3.8–5.0%  repeatability  and  3.8%–7.9%
intermediate  precision.  Furthermore,  system  suitability  criteria  were  developed  to guarantee  long-term
stability  of  this  assay  in a regulated  production  environment.  SRID  is  fraught  with  methodological  and
logistical  difﬁculties  and  the  determination  of the  HA content  requires  the  acceptance  of  new  and  mod-
ern release  assays,  but until  that  moment,  the described  parallel  line  model  represents  a  signiﬁcant  and
robust update  for the  current  global  inﬂuenza  vaccine  release  assay.. Introduction
Inﬂuenza is a serious respiratory disease caused by an inﬂuenza
irus infection and is responsible for severe complications in par-
icularly the elderly and individuals at risk. Vaccination is the
ost common and effective prophylactic measure to prevent
nﬂuenza and is annually recommended. Inﬂuenza virus infec-
ions have a seasonal appearance in moderate climates, being most
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predominant in the late fall and early winter (in the Northern hemi-
sphere November–January, and Southern hemisphere May–June).
Due to antigenic drift of the inﬂuenza virus’ major glycoproteins,
the antigenic make-up of the virus changes rapidly over a season.
Consequently, the strain composition of the inﬂuenza vaccines is
updated annually per hemisphere to represent the epidemiological
situation in the ﬁeld. Recommendation of vaccine strains is under
the auspices of the World Health Organization, who have inﬂuenza
reference laboratories in their network worldwide responsible for
virus surveillance and vaccine strain selection. As a consequence,
the inﬂuenza vaccine manufacturing and control process cycles
have to be adapted annually to strain changes. Hence, vaccine pro-
duction, registration and batch release have to be completed under
daunting timelines to guarantee timely vaccine availability for the
population.
Key aspect of vaccine manufacturing is the establishment of
potency, since vaccines are formulated based on potency. The
potency of inﬂuenza vaccines is evaluated immunochemically by
their content of haemagglutinin (HA), which is the most abundant
and immunogenic viral surface antigen of inﬂuenza. This is deter-
mined by single radial immunodiffusion (SRID) [1–3]. SRID builds
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n the interaction between HA and a strain-speciﬁc polyclonal anti-
ody against HA which is dissolved in an agarose-gel. In fact what
he assay measures is the quantity of antigen as a function of its
mmunogenic properties.
During the incubation in the agarose gel, the virus HA protein
igrates through the gel and interacts with the antibody. As a result
 ring of precipitated virus–antibody complexes is formed which
an be visualized after appropriate staining of the gel. Through
he use of a statistical comparison between the dilution series of
he standard and the dilution series of the test sample the (rel-
tive) concentration of HA in the test sample can be quantiﬁed.
istorically, the surface area of the diffusion zone in the SRID assay
as deemed linearly related to the dose of preparation tested [4]
nd it has therefore been analyzed by the slope ratio method [1,5].
RID has been the required release assay for the inﬂuenza vaccines
orldwide as laid down in regulatory documents by the European
edicines Agency and Food and Drug Administration. The reagents
f the SRID test are standardized over the manufacturers and gov-
rnment institutes and are consequently provided by government
nstitutes like NIBSC for Europe, TGA for Australia and CBER for the
SA.
Despite these advantages however, the SRID assay is cumber-
ome and labor-intensive and requires the generation of large
mounts of calibrated standard antigen and polyclonal HA-speciﬁc
ntibody in sheep, which imposes considerable lead times as well.
o far, SRID reagents have been mainly produced using virus grown
n fertilized eggs. However, in recent years, quality considerations,
he susceptibility of eggs for recent strains of inﬂuenza and the
ear of limited egg, and hence vaccine supply in case of a new
nﬂuenza pandemic have initiated the development of vaccines
roduced using cell culturing. In absence of an improved alter-
ative antigen quantiﬁcation and vaccine release assay accepted
y regulatory bodies a re-evaluation of SRID HA quantiﬁcation by
lope-ratio method is warranted.
The dose–response relationship in the SRID assay is essentially
on-linear and sigmoid when a wide range of doses is applied,
hich is a general feature of bioassays. A slope ratio model may
pproximate the dose–response relationship near the asymptotes
n a smaller range of doses, requiring less concentration levels
1,5]. Important assumptions of the slope ratio model are common
ntercepts between standard and test sample and linearity in con-
entration. However, manufacturing variances which are inherent
o biological processing may  impact also the behavior of samples
n the SRID assay which could violate the assumption of common
ntercepts and cause curvature in the dose–response relation.
An alternative to the slope ratio model is the parallel line model,
pplied to the dose region with the steepest slope. In this region the
ost efﬁcient estimation of relative potency can be obtained [6].
he parallel line model allows for different intercepts between the
tandard and test samples, but requires common slopes for all sam-
les. Furthermore, it should satisfy linearity in the logarithmically
ransformed concentration or log dose.
This paper outlines the development and qualiﬁcation of a
arallel line model for analysis of SRID quantiﬁcation of HA in
ell culture-derived whole virus ﬁnal monovalent and trivalent
nﬂuenza vaccines according to pharmaceutical guidelines [7].
dditionally, the quality and stability of the assay in time are mon-
tored by means of system suitability testing for reference samples.
. Materials and methods.1. Materials
Reference HA antigen and anti-HA sera were obtained from
he National Institute for Biological Standards and Control (NIBSC,Fig. 1. SRID Immunodiffusion plate after overnight incubation and coloring.
Potters Bar, UK). Reference antigen was prepared from formalin
inactivated, partially puriﬁed inﬂuenza viruses which was sus-
pended in PBSA buffer containing 1% (w/v) sucrose and processed
for freeze-drying in 1 mL  volumes as described in [8].  The antiserum
reagent was prepared in sheep to the puriﬁed HA of the correspond-
ing inﬂuenza strain. Sheep were vaccinated twice intramuscularly
with Freund’s complete adjuvant (FCA). Four to six weeks after the
initial immunization, serum was  collected and sodium azide (0.05%
w/v) was added.
2.2. Determination of the speciﬁc HA antigen content
The concentration of HA in the different inﬂuenza virus antigen
preparations was  determined by SRID [1].  In short, a 1% agarose
solution in 0.01 M phosphate buffered saline solution prepared and
poured into plastic trays. After the gel has set and has been trans-
ferred to a glass plate, 4.5 mm holes are punched in the gel. Each
plate contained randomized, independent dilution series of stan-
dard antigen and test sample, both pretreated for 30 min  with 1:10
detergent. The range of the standard curve is separately determined
for each inﬂuenza strain prior to routine use. Twenty microlitres of
the standard antigen or test sample is added to the wells of the
plate and incubated for 18 h at ambient temperature (AT). After
incubation, the plates are washed with water-for-injection (WFI)
and placed on clean glass-plate. A pre-wet blotting paper is placed
on top of the gel and dried in a stove at 60 ◦C for 3–8 h. Next, the gel
is stained in Coomassie brilliant blue (Sigma) and incubated until
precipitation rings are clearly visible (15–60 min) (Fig. 1). The gel
is washed for 15–30 min  with WFI  or until the background staining
has sufﬁciently been reduced and ﬁnally dried at AT. The diameter
of the formed precipitation rings is measured perpendicular in two
directions using a micrometer lens (accuracy 0.1 mm),  from which
a diffusion area is calculated.
2.3. Methodological assumptions
2.3.1. Similarity
An important assumption in biological assays is that of similar-
ity. Two  preparations are similar if one preparation behaves as a
dilution of the other preparation [9].  A consequence of similarity
for linear dose–response relationships in log dose is that the regres-
sion lines of the two  preparations must have equal slopes, i.e. are
parallel. Statistical tests on linearity and parallelism are deﬁned in
Sections 2.4.2 and 2.4.3.
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Table 1
Concentration ranges for the standard and test sample for seasonal and pandemic inﬂuenza virus studies.
Concentration (g/mL)
Seasonal 8.1 9.2 10.5 12.0 13.7 15.6 17.8 20.2 23.1 26.3 30
















































Test  × × 
.3.2. Dose range and assay response
An essential part of the development of the parallel line assay is
he determination of the linear part of the dose–response curve. A
reliminary study with a wide concentration range was performed
o determine the preferred concentration range for the assay in
ombination with a possible mathematical transformation of the
iffusion areas as assay response.
.3.3. Intra-plate variation
Possible non-random patterns on the 36-well plates were inves-
igated by performing experiments with plates ﬁlled with equally
oncentrated wells. Several situations are known in which system-
tic, mainly parabolic, patterns occur in biological assays with well
lates. Such a pattern could disturb the regression lines and the con-
lusions of the statistical analysis and may  cause a bias in potency
stimation.
.3.4. Plate design
In Table 1 the concentrations of the standard sample and the
est sample are presented for both the seasonal and pandemic
nﬂuenza virus study. These concentrations are prepared in three-
old through three independent dilution series. Three remaining
ells on the 36-well plate are available for quality control purposes.
n total, three 36-well plates are used per assay run and different
andomization schemes are used for the plate layouts. Instead of
enerating a completely random plate design each time the assay
s run, only nine plate designs were used by the analysts in a cyclic
ashion. The nine designs were created randomly. For each routine
ssay with three plates the analysts must use three different plate
esigns taken from these nine plate designs. This pseudo-random
pproach for running routine assays would approximate a pure ran-
om approach, while limiting the number of execution errors by
nalysts. To eliminate possible systematic differences in diffusion
reas between dilution series the average of the assay responses
er sample, concentration, and plate is taken for estimation of the




The six and ﬁve concentrations for the standard sample and test
ample, respectively, allow us to detect observations that deviate
everely from the statistical models. Extremely outlying observa-
ions are determined through the externally studentized residuals
R-student) of the full linear and common quadratic model, see
ection 2.4.2. If the absolute value of an R-student is larger than
 in one of the two models and larger than 3 in the other model,
hen the observation for the particular concentration is considered
n extreme outlying observation and it is removed from further
nalysis, see in Fig. 2..4.2. Statistical models
The parallel line model is mathematically deﬁned by
ijk = ˛ij + ˇixijk + εijk (PL), where y, ˛, ˇ, x, and ε represent the
verage log surface area, the intercept, the slope, the log dose, and× × ×
× × ×
the residual error, respectively, and the subscripts i, j, and k rep-
resent the plate, the sample, and the concentration, respectively.
The residual error εijk is assumed to be normally distributed with
expectation zero and constant variance.
Besides the PL model, the more comprehensive models full lin-
ear (FL), common quadratic (CQ), and full quadratic (FQ) will be
used in the procedure for testing the model adequacy [10]. Com-
pared to the PL model, the FL model includes a slope for each sample
separately, i.e. ˇij is used instead of ˇi. The CQ and FQ model include
quadratic terms for log dose with common parameters per plate to
both samples. The CQ model adds a term ix2ijk to the FL model and
separate parameters for the quadratic term for samples per plate
(ijx2ijk) are used in the FQ model.
For the parallel line model linearity should hold. It can
however be violated in two  different ways [9, p. 95]. Systematic
non-linearity is a violation of linearity that is similar for the stan-
dard and the test sample per plate. This means that non-linearity
or curvature has the same direction for both samples. It is tested
by a comparison of the FL model with the CQ model by means of
an F-test [10]. Considerable, but completely erratic, scatter around
the curves may  also cause violation of linearity when model FL is
compared to FQ by means of an F-test [10], but this type of non-
linearity will hardly affect the test for systematic non-linearity
[9]. It should not be confused with heterogeneity of the residual
variance with respect to dose. Considerable scatter would indicate
a dose–response relationship that cannot be improved since the
deviation from linearity is random or arbitrary.
In case the PL model is appropriate (see Section 2.4.3), it is imper-
ative that the slope of the regression line deviates signiﬁcantly from
zero, otherwise no potency can be estimated. Indeed, if the slope
would be zero, then the diluted samples of the standard and the test
sample would have the same expected response value and there is
no way  of establishing the relative activity of the test sample with
respect to the standard sample. The slopes are tested by means of
a t-test .
2.4.3. Biological assumptions
The key assumption for the analysis of a dilution assay is that
the standard and test samples contain the same functional protein,
but possible in different ratios, which implies similar behavior in
the bioassay. This biological similarity implies statistical similarity,
i.e. the standard and test curves in the SRID assay are parallel. As a
consequence, failure to satisfy statistical similarity may be taken as
evidence against biological similarity [11]. Parallelism is tested by
means of an F-test [10] that compares the PL model to the FL model
. If parallelism is rejected, an estimate for the relative activity of
the test sample cannot be given.
2.4.4. Estimation procedure
The ﬂow diagram in Fig. 2 presents the step-by-step actions
employed for determining the relative HA content based on an ana-
lytical run of three plates. It starts with the data validation (Section
2.4.1) step. The second step is testing for linearity (Section 2.4.2)
and parallelism (Section 2.4.3) . A signiﬁcance level of 0.01 is
used for the corresponding F-tests. If systematic non-linearity is
observed it may  be caused by the inherent non-linear and convex

















rig. 2. Flow diagram for the determination of the relative HA content for three pla
espectively.
ose–response relationship for the selected dose range. Removal
f the highest concentrations for the two samples is conducted to
olve the systematic non-linearity, ﬁrst for the standard sample
nd then possibly for the test sample . Due to convexity, it
s expected that the highest concentrations will deviate most from
inearity. The ﬁnal step is testing the magnitude of the individual
lopes at the 0.001 signiﬁcance level (Section 2.4.2) . If the slope
s not highly signiﬁcantly different from zero for a plate, then no
ctivity estimate can be calculated for this plate . Note that this
late is still used for estimation of the residual error.
Removal of data should be limited to a minimum. Five and four
oncentrations for the standard and test sample per plate, respec-
ively, are set as minimum requirements for the estimation of the
elative activity per plate . This implies that at most one concen-
ration per sample per plate can be removed based on statistical
easons. In case more data should be removed for a particularithin an analytical run with six and ﬁve dilutions of the standard and test sample,
sample on a plate, then the entire plate will be discarded. A min-
imum of two  plates is set as a requirement . If the removal of
more than one concentration for a sample on the remaining two
plates is needed, then the assay is discarded and no activity for the
test sample is calculated .
2.4.5. Activity estimation
Based on the PL model the estimated log transformed relative
activity for plate i is determined by means of the following for-
mula
ˆi =
ˆ˛ iT − ˆ˛ iS , (1)ˆˇ
i
with T the test sample and S the standard sample. The derivation of
a conﬁdence interval for the relative activity is based on Fieller’s
theorem [9].  The combination of the log transformed relative
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Table 2
P-values for the tests on considerable scatter (SCAT), systematic non-linearity (LIN), and parallelism (PAR) initially and if not passed after removal of the highest concentration
of  the standard sample. The seasonal viruses 1, 2, and 3 represent IVR-145, IVR-142, and B-Mal, respectively. The pandemic virus 1 is NIBRG-14.
Product Run Analyst Virus Batch Initial P-values P-values after removing the highest
concentration of the standard sample
PSCAT PLIN PPAR PSCAT PLIN PPAR
Seasonal 1 1 1 1 0.089 0.069 0.005 0.172 0.085 0.020
2 1  1 2 0.785 0.642 0.930
3  1 2 1 0.033 0.010 0.401
4  1 2 2 0.252 0.304 0.166
5  1 3 1 0.330 0.413 0.649
6  1 3 2 0.531 0.459 0.215
7 2 1 1 0.035 0.116 0.322
8 2 1 2 0.005 0.002 0.104 0.072 0.042 0.078
9  2 2 1 0.946 0.960 0.702
10  2 2 2 0.002 0.001 0.046 0.100 0.060 0.811
11  2 3 1 0.234 0.110 0.158
12  2 3 2 0.132 0.043 0.002 0.912 0.623 0.041
13  3 1 1 0.208 0.374 0.012
14  3 1 2 0.063 0.033 0.337
15  3 2 1 0.173 0.052 0.028
16  3 2 2 0.013 0.009 0.000 0.157 0.140 0.020
17 3 3 1 0.289 0.316 0.333
18  3 3 2 0.020 0.046 0.112
Pandemic 1 1 1 1 0.006 0.019 0.450
2  1 1 1 0.215 0.976 0.068

































a4  1 1 1 
ctivities from the individual plates is determined with the method
f Bliss [12]. It is a weighted average of the estimates in (1),
ut the choice of weights depends on homogeneity of activi-
ies between plates. Since the residual variance of the parallel
ine model (PL) is pooled over all plates, the average number of
egrees of freedom for each plate, used in the method of Bliss,
s taken equal to the residual variance number of degrees of
reedom.
To preserve sufﬁcient precision of the combined relative activ-
ty estimate an upper bound is set for the ‘½L-value’. The ½L-value
s deﬁned as half the distance between the lower and upper con-
dence limit for the combined log transformed relative activity. In
outine analysis, the ½L-value can always be met  by performing
dditional runs for the particular test sample and combine them
sing the method of Bliss.
To obtain an estimate of the absolute HA content the estimate
f the relative HA content with conﬁdence interval should be mul-
iplied by the pre-dilution factor and by the initial estimates of the
re-diluted test sample.
.4.6. Quality control
To monitor the quality and stability of the assay in time sys-
em suitability tests for the reference samples of routine analyses
re introduced. From the diffusion areas of the reference sam-
les, the reference concentration for a plate is estimated by an
nverse calculation of the estimated regression line of the standard
ample. Three-sigma control limits will be set for two different
tatistics, i.e. the geometric average of the estimated concentra-
ions and the ratio of the maximum and minimum concentration
or the three plates in an analytical run. In the logarithmic scale
he statistics represent an arithmetic average and a range, for
hich standard approaches may  be used to calculate controlimits [13].
Reference samples outside the control limits indicate unreliable
nalytical runs [11]. The regarding analytical runs will then be dis-
arded for estimating the relative activity of a test sample in routine
nalysis.9 0.987 0.660
2.5. Method qualiﬁcation
For a precision study for an inactivated, whole virion, sea-
sonal inﬂuenza vaccine, three viruses were used: H1N1 A/Solomon
Islands/3/2006 (IVR-145), H3N2 A/Hiroshima/52/2005 (IVR-142)
and B/Malaysia/2506/2004 (B-Mal). These reagents were analyzed
by three analysts on six different days. For each virus two  batches
were analyzed in triplicate, i.e. in three analytical runs. Thus, in total
54 plates are used in 18 analytical runs which are unique combina-
tions of viruses, analysts and batches, see Table 2. For inactivated,
whole virion, pandemic inﬂuenza vaccine a moderated precision
study was  performed with virus A/Vietnam/1194/2004–NIBRG-14
(NIBRG-14) in four analytical runs.
Mixed effects analysis of variance models on the log trans-
formed relative activity estimates for the seasonal and pandemic
inﬂuenza virus studies separately, are used to estimate the repeata-
bility and intermediate precision for routine analysis with two  and
three plates. The precision estimates will be expressed as relative
standard deviations in the original scale of relative HA contents.
3. Results
3.1. Methodological assumptions
The ﬁrst step in the development phase was to try to ﬁt the
slope-ratio model, since this was  the current method in liter-
ature [1,5]. Unfortunately, the similarity condition of the slope
ratio model, i.e. common intercepts, regularly failed. In Fig. 3 two
examples are presented where the FL model is ﬁtted to the data.
Additionally, the linearity in dose for the surface area for the
selected dose range was  also violated frequently. This initiated an
investigation of possible row and column effects on plates and an
investigation of the shape of the dose–response relationship on a
large range of doses.Two  experimental plates ﬁlled with equally concentrated wells,
of which the average log surface areas are visually presented in
Fig. 4, did not show clear systematic patterns like deviating dif-
fusion areas near the edges of the plate. However, it did show
206 G. van Kessel et al. / Vaccine 30 (2012) 201– 209
Fig. 3. Two examples of plate results for the slope ratio model with the surface areas of the test sample and the standard sample () related to the predicted lines of the

























good ﬁt of the selected parallel line model. Fig. 6a shows a testest  sample and the standard sample (—) plotted against concentration base
elatively high variability between the different positions on
he plate dictating (three) replicates per sample and dilution to
educe the within-plate variability. Randomization schemes for
late-layout are introduced to overcome possible unrecognized
ystematic patterns, see Section 2.3.4. Non-random plate-layout
ay  have been applied when a clear systematic pattern was
bserved to accommodate systematic differences between wells
e.g. split-plot designs).
The shape of the dose–response curve was investigated by
bserving a wide range of concentrations from approximately 7.5
o 180 g/mL (Fig. 5). The curve for the log-surface area against
og-dose is ‘mostly’ linear between 15 g/mL and 70 g/mL. As
xpected, the curves ﬂatten both on the left and on the right side
nd the steepest part is the middle. This suggests the possible use
f a parallel line model in this dose range, since a linear relation
s observed in log-dose instead of dose [6].  The concentration of
he WHO  recommended SRID reagents for standardization of sea-
onal and pandemic inﬂuenza vaccines are lot-speciﬁc and limited
o 30 g/mL and 50 g/mL in our studies, respectively. To achieve
 range that is wide enough to accurately determine the regression
ines the selected concentrations range from 8 to 30 g/mL and
rom 13 to 50 g/mL for seasonal and pandemic inﬂuenza vaccine,
espectively.
ig. 4. Average log-surface area of two experimental plates with equally concen-
rated wells to examine possible row/column patterns.he full linear model (FL).
3.2. System suitability
The estimation procedure in Fig. 2 was  applied to verify the
system suitability in the precision studies. The results of the tests
on systematic non-linearity, considerable scatter, and parallelism
are presented in Table 2. It can be seen that initially for analytical
runs 1, 8, 10, 12, and 16 for the seasonal inﬂuenza vaccine viola-
tions against the parallel line model occurred, because the P-values
for systematic non-linearity and considerable scatter and/or the
P-value for parallelism are below 0.01. Apparently, all model vio-
lations were solved by removing the highest concentration of the
standard sample. However, for two  plates in analytical run 9 no
accurate determination of the activities was possible, because the
slopes were not signiﬁcantly deviating from zero at signiﬁcance
level 0.001. Since both plates belong to the same analytical run, this
batch could not have been released in routine analysis because only
one plate remains. The suitability of the PL model is presented in
Fig. 6. The observations for the standard and test sample are close
to their corresponding ﬁtted lines (PL) and they follow a reason-
able random pattern around the line, while the estimated model
assumed parallelism between the samples. This demonstrates asample that is stronger than the standard sample and Fig. 6b shows
a weaker test sample compared to the standard sample.
Fig. 5. Range/linear part of curve determination for seasonal inﬂuenza vaccine using
test  sample and standard sample () dilution series.
G. van Kessel et al. / Vaccine 30 (2012) 201– 209 207
Fig. 6. Two  examples of plate results for seasonal (a) and pandemic (b) inﬂuenza vaccine 
to  the predicted lines of the test sample and the standard sample (—) plotted agai
Fig. 7. Combined relative HA contents (in % RSD) per analytical run with 95% con-
















vaccines were based on the six validation runs, while the limits
T
RVR-145 (×, *), IVR-142 ( , ), and B-Mal (, ) were used and one batch of
andemic NIBRG-14 (+).
.3. Relative activity estimates
Based on the potency estimates for all acceptable plates, the
ombined relative activity estimates per assay run were com-
uted according to the method of Bliss [12]. The results with 95%
onﬁdence intervals are visually presented in Fig. 7. The relative
ctivities are estimated between 74.4% and 129.9%, but the relative
ctivity of 129.9% in run 8 is somewhat deviating from the others.
t was however not discarded from further precision calculations.
The upper limit for the ½L-value for routine analyses is based
n the seasonal inﬂuenza vaccine data alone and it is determined
t 14.4%. This means that the upper 95% conﬁdence limit for the
ombined relative activity should not be higher than 14.4% of the
ombined estimate of the activity. This is substantially better than
5%, which is usually accepted for potency assays by external
uthorities. The pandemic inﬂuenza vaccine data showed slightly
able 3
epeatability and intermediate precision for the relative HA content (RSD in %) for the av
2 plates 
Seasonal 
Repeatability (95% CI) 4.95 (3.99, 6.52) 
Intermediate precision (95% CI) 7.93 (5.90, 12.1) with the log-surface areas of the test sample and the standard sample () related
nst log-concentration based on the parallel line model (PL).
higher ½L-values for the ﬁrst two  runs, but the conservative upper
limit was  not adjusted for this virus.
3.4. Method qualiﬁcation
The estimated measures of precision for a combined relative
HA content obtained with two  or three plates together with their
95% conﬁdence intervals are presented in Table 3 for the sea-
sonal and pandemic inﬂuenza vaccines. Repeatability represents
the intra-assay variation and indicates the variation within one rou-
tine assay run keeping other factors ﬁxed, e.g. analysts and testing
days. Intermediate precision represents the inter-assay variation
and indicates the variation between and within assay runs chang-
ing typical factors within the laboratory, e.g. analysts and testing
days. These are commonly used measures of precision for valida-
tion of biological and analytical methods, see [7].  The precision
studies demonstrate a repeatability ranging from 3.8 to 5.0% and
intermediate precision ranging from 3.8 to 7.9%. These precision
measures are quite small, since precision of 15% is not unrealistic
for bioassays.
3.4.1. Quality control
The three sigma lower and upper control limits for the geo-
metric average of three concentration estimates in routine analysis
(in g/mL) are 11.7 and 18.4, 11.6 and 18.2, 13.0 and 20.5, and
42.1 and 58.6 for the seasonal IVR-145, IVR-142, and B-Mal, and
the pandemic NIBRG-14 inﬂuenza vaccines, respectively. Note that
the theoretical reference concentrations equal 15 and 50 g/mL
for seasonal and pandemic inﬂuenza vaccines, respectively. The
upper limit for the ratio of the largest and smallest concentration
per plate was estimated at 169%, 139%, 128%, and 134% for the
above-mentioned vaccines, respectively. The limits for the seasonalfor the pandemic vaccines were based on an extensive set of more
than 100 routine and qualiﬁcation analytical runs, performed in a
1.5-year period (data not shown).
erage of 2 and 3 plates for seasonal and pandemic inﬂuenza virus studies.
3 plates
Pandemic Seasonal Pandemic
4.64 (3.13, 8.90) 4.04 (3.26, 5.32) 3.79 (2.56, 7.26)
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. Discussion
The proposed parallel line method presented in this paper rep-
esents a modern follow-up to previously published slope-ratio
odels [1,5]. Slope ratio models may  be easier to use than parallel
ine models, but slope ratio models are used near the lower asymp-
ote of the sigmoid dose–response relationship where estimation
s less efﬁcient than in the region with the steepest slope, where
he parallel line model is applied [6]. This argument and the fact
hat in the development phase the slope ratio model failed more
ften on linearity than the parallel line model, moved us to develop
 robust and precise assay based on the parallel line model.
Since the parallel line model is an approximation of the true
nderlying non-linear dose–response relationship, only severe vio-
ations of the model assumptions should prevent the calculation of
 relative HA content. This has led us to more stringent signiﬁcant
evels than the recommended 0.05 of the European pharmacopoeia
10]. This is in line with the philosophy described in the USP [14]
ecommending equivalence testing to compensate for frequent
rrelevant model violations.
To make the approach more robust, the highest concentrations
nd outliers are occasionally removed to improve the model ﬁt.
he involved risk of such a procedure is the introduction of bias
nd underestimation of assay precision. However, this does not
eem to be the case for the estimation procedure in Fig. 2. A small
imulation study of a parallel standard and test sample (3 plates
imulated 10,000 times) showed a bias of less than 0.01%. The con-
dence interval for the combined activity included the true activity
ith 95.9% coverage. Only 3.0% of the simulation runs contained an
xtreme outlier, only 1.4% of the simulation runs removed the high-
st concentration of the standard, and only 0.25% of the simulation
uns excluded one plate for potency calculations. This simulation
tudy showed that the estimation procedure does not introduce
ias and the removal of data under ideal situations is limited.
Compared to previous studies on SRID [5,15],  the estimated
recision of our parallel line assay is relatively low (3.8–7.9% for
ntermediate precision). The improvement comes partly from the
arallel line model, but also from the three plates per analytical run,
hich makes it a more labor-intensive assay. On the other hand,
one of the previous studies performed such an elaborate precision
tudy as ours, which implies that the precision of the slope-ratio
ssays in previous studies is possibly underestimated. Furthermore,
he precision study of the pandemic inﬂuenza vaccine, which was
xecuted approximately one year after the seasonal inﬂuenza vac-
ine study, showed no relevant between-assay run variation, which
as relevant for the seasonal inﬂuenza study. A possible reason for
he decrease is the improved experience of the analysts with the
ssay, which may  imply an even better assay precision for SRID
han reported.
An additional study has been performed (data not shown) at
ery low concentrations (3–8 g/mL) to judge the validity of the
arallel line model in this area. It was concluded that the parallel
ine model frequently holds, but two notes should be made. The
arallel line model is rejected in relatively more cases, due to non-
inearity or non-parallelism. On the other hand, the variability of
he activity estimates increases due to shallower slopes near the
ower asymptote of the sigmoid dose–response curve. To achieve
imilar precision as obtained in the validation studies presented
n this paper, either more plates should be analyzed for the same
ample or an increased series of dilutions may  be implemented at
he cost of a lower number of concentrations.
In the last decade, the development of alternative biopotency
ssays for the quantiﬁcation of human inﬂuenza haemagglutinin
as been published such as HPLC methods [16,17],  enzyme linked
mmunosorbent assays (ELISAs) [18,19], neuraminidase (NA) activ-
ty assays [20,21], quantitative PCR [22,23] and surface plasma 30 (2012) 201– 209
resonance [15]. Most of these methods show increased sensitivity
compared to SRID. Although some of these methods barely reduce
the hands on time, the main impediment for global authorization as
vaccine release assay of commercially available inﬂuenza vaccine
has been the lack of correlation with the antibody to HA binding
with responses in man  [24,25]. The use of HPLC has been the most
prominent and has been shown to be applicable to both cell culture
and egg-derived inﬂuenza vaccines [16,17]. Regulatory agencies
have also granted the use of HPLC for in-process controlling
during vaccine production in case of a nascent inﬂuenza pandemic.
Thereby recognizing the promise of these assays which through
their increased speciﬁcity make up for the lack in possible detection
of biological function.
Whether the concept of the parallel line method presented in
this paper would further improve the performance of the SRID
alternatives is unclear and needs to be evaluated in the future.
With the current precision and stability of the presented SRID
assay, comparison studies with other methods can be performed
to demonstrate equivalence. However, in resource-poor settings
the use of the low-cost SRID is likely to be the preferred method.
On the road towards full validation, the next step in the devel-
opment of the SRID will be to formally determine the accuracy and
robustness of the assay. The accuracy can be determined by testing
the standard at different concentrations and compare the observed
activity with the declared activity. It is expected that it will perform
adequately, since the SRID assay adequately operates even at very
low concentrations. Furthermore, the control limits for the refer-
ence sample for pandemic inﬂuenza over more than 100 analytical
runs, shows good stability, which means that robustness might not
be a true issue, otherwise the control would have shown much
higher variation. Note that the corresponding three sigma control
limits are within 80% to 125% of the nominal value.
During the study described, egg-derived HA antigens were used
as standard antigen in SRID while the test samples contained cell
culture-derived HA. Egg-derived antigens are currently the only
supplied reagents worldwide. This heterogeneity in antigen did not
have an effect on the HA estimation by slope ratio method [26]. It
remains to be investigated whether a parallel line model is affected
by the use of a standard heterologous to the test sample.
5. Conclusions
In this paper we present, for the ﬁrst time since the initial
description of the SRID assay in the 1980s, an updated and robust
statistical parallel line method that can be used for the quantiﬁca-
tion of HA protein in human inﬂuenza vaccines by SRID. The ﬁnal
method enables the user to accurately quantify the active ingredi-
ent and is therefore an important tool during the production and
release of inactivated inﬂuenza vaccines. The method represents a
next chapter of statistical methods for the quantiﬁcation of HA in
inﬂuenza vaccines. Inﬂuenza vaccines need to be available at the
start of the inﬂuenza season in the fall which imposes a limited
window in which the production and release of vaccines needs to
be completed. All improvements to the SRID assay that enhance
precision are welcome, bearing in mind that the assay has ﬁnite
boundaries of optimization as compared to the more speciﬁc bio-
chemical assays. The SRID assay in its current form requires annual
update of reagents and re-validation, adding to the risk of untimely
release of inﬂuenza vaccines.
Until a next generation release assay is accepted for the global
release of (inter-) pandemic inactivated inﬂuenza vaccines, the
SRID is the only assay which can be used for batch release. By
improving the accuracy of quantiﬁcation of the active ingredient
HA by SRID, the chance of possible retests is diminished there-
fore creating a more robust endgame for vaccine production and
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ossible pandemic, as recently seen with the worldwide H1N1
wine inﬂuenza pandemic in 2009, a healthy release procedure is
ven more warranted.
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